Shukra Pharmaceuticals (Small Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Shukra Pharmaceuticals Limited |
|||
|
Price: ₹21.85 (-1.8%) | ||
| 52 Week Low: ₹5.75 52 Week High: ₹27.15 |
|||
| Market Capital: 17.42 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Shukra Pharmaceuticals Share Price Target For 2025
- 1.1.1: Shukra Pharmaceuticals Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Shukra Pharmaceuticals Share Price Target For 2026
- 1.2.1: Shukra Pharmaceuticals Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Shukra Pharmaceuticals Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Shukra Pharmaceuticals Financial Performance
- 3.0.1: Is Shukra Pharmaceuticals A Good Buy For Long Term?
Shukra Pharmaceuticals, a Small Cap company has delivered 128.6% returns in 5-year with 23.0% profit margin, making it a potential Multibagger.
To predict the Shukra Pharmaceuticals's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Shukra Pharmaceuticals Share Price Target For 2025
The line chart displays the monthly closing prices of Shukra Pharmaceuticals with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Shukra Pharmaceuticals shares in 2025, see the table below.
Shukra Pharmaceuticals Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 59.5 (+172.31%) | Price Action: 22 Nov 2024 High |
| 2025 Target 2 | 58.52 (+167.82%) | Price Action: 19 Aug 2024 Low |
| 2025 Target 1 | 57.52 (+163.24%) | Price Action: 21 Nov 2024 Low |
| Current Price | 21.85 | Shukra Pharmaceuticals's share price as of 28 Mar 2025 |
| Stop Loss 1 | 5.92 (-72.91%) | Price Action: Chart |
| Stop Loss 2 | 5.86 (-73.19%) | Price Action: Chart |
| Stop Loss 3 | 5.75 (-73.69%) | Price Action: Chart |
Short-Term Technical Outlook
Current Technical Position: Shukra Pharmaceuticals is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹189.62 serves as the nearest technical reference point.
Historical Returns: 3-month: -83.98% | 6-month: -69.15% | 1-year: -93.2%
Shukra Pharmaceuticals Share Price Target For 2026
The line chart displays the monthly closing prices of Shukra Pharmaceuticals with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Shukra Pharmaceuticals shares in 2026, see the table below.
Shukra Pharmaceuticals Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 250.7 (+1,047.35%) | Price Action: 17 Mar 2025 High |
| 2026 Target 2 | 245.7 (+1,024.48%) | Price Action: 18 Mar 2025 High |
| 2026 Target 1 | 240.8 (+1,002.05%) | Price Action: 19 Mar 2025 High |
| Current Price | 21.85 | Shukra Pharmaceuticals's share price as of 28 Mar 2025 |
| Stop Loss 1 | -35.59 (-262.89%) | Price Action: Chart |
| Stop Loss 2 | -35.23 (-261.24%) | Price Action: Chart |
| Stop Loss 3 | -34.6 (-258.36%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Shukra Pharmaceuticals is currently trading near its 52-week high of ₹27.15, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -93.2% | 3-year: +76.78% | 5-year: +128.56%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Shukra Pharmaceuticals Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹21.85 | ||
| 2025 | ₹284.50 | +1,202.05% | ₹288.77 |
| 2026 | ₹532.60 | +87.2% | ₹540.59 |
| 2027 | ₹746.85 | +40.22% | ₹758.05 |
| 2028 | ₹1,141.52 | +52.84% | ₹1,158.64 |
| 2029 | ₹1,902.01 | +66.62% | ₹1,930.54 |
| 2030 | ₹2,606.40 | +37.03% | ₹2,645.50 |
| 2031 | ₹3,833.07 | +47.06% | ₹3,890.57 |
| 2032 | ₹5,303.42 | +38.35% | ₹5,382.97 |
| 2033 | ₹6,904.46 | +30.18% | ₹7,008.03 |
| 2034 | ₹9,331.99 | +35.15% | ₹9,471.97 |
| 2035 | ₹12,318.58 | +32% | ₹12,503.36 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Shukra Pharmaceuticals Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 17.42 Crore | Market valuation of Shukra Pharmaceuticals's shares. |
| Revenue (TTM) | 58.83 Crore | Total revenue generated by Shukra Pharmaceuticals over the past twelve months. |
| Net Income (TTM) | +4.4 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +7.98% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +22.97% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-23.33% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
0.05 | Company's total debt divided by total shareholder equity. |
| Total Debt | 2.3 Crore | Sum of Shukra Pharmaceuticals's current & long-term financial obligations. |
Is Shukra Pharmaceuticals A Good Buy For Long Term?
Shukra Pharmaceuticals, with a market cap of 17.42 Crore, has recently reported a revenue of 58.83 Crore and a net profit of 4.4 Crore. While the company has experienced a quarterly revenue decline of 23.33%, it maintains a healthy profit margin of 22.97%. Despite a debt of 2.3 Crore, Shukra Pharmaceuticals has delivered impressive long-term returns, including a remarkable 1220.16% over the past 3 years. Considering these factors, the stock appears to be an average buy for long-term investors seeking moderate growth potential.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
